Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

310 results found

2023 ∙ NACI

Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix

  • Background paper
  • Americas
  • Canada
  • Pneumococcal disease
Download:
2023 ∙ NACI

Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines

  • Recommendation
  • Americas
  • Canada
  • Older adults
  • Adults
  • Pneumococcal disease
Download:
2023 ∙ NACI

Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations

  • Recommendation
  • Americas
  • Canada
  • Newborn
  • Pneumococcal disease
Download:
2023 ∙ Conseil Supérieur de la Santé (CSS)

Pneumococcal vaccination in children and adolescents in Belgium

  • Recommendation
  • Europe
  • Belgium
  • Children
  • Adolescents
  • Pneumococcal disease
Download:
2022 ∙ Nor, S. F. S. Aminuddin, N. A. Ahmad, N. Hassan, M. R. Nawi, A. M. Ahmad, N. Pang, N. T. P. Omar, A. Madrim, M. F. Mokti, K. Ramdzan, A. R. Rahim, S. S. S. A. Jeffree, M. S.

A Systematic Review and Meta-Analysis of Mobile Phone Messaging Intervention on Vaccine Preventable Diseases

  • Adults
  • Parents/caregivers
  • Pregnant women
  • Influenza
  • Pneumococcal disease
  • Mumps
  • Measles
  • Rubella
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2022 ∙ Mungall, B. A. Hoet, B. Nieto Guevara, J. Soumahoro, L.

A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children

  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Administration
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Parmar, K. Subramanyam, S. Del Rio-Pertuz, G. Sethi, P. Argueta-Sosa, E.

Cardiac Adverse Events after Vaccination—A Systematic Review

  • Adults
  • COVID-19
  • Smallpox
  • Influenza
  • Pneumococcal disease
  • Tetanus
  • Cholera
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Cardoso Pinto, A. M. Ranasinghe, L. Dodd, P. J. Budhathoki, S. S. Seddon, J. A. Whittaker, E.

Disruptions to routine childhood vaccinations in low- and middle-income countries during the COVID-19 pandemic: A systematic review

  • Newborn
  • Children
  • Low and Middle Income Countries
  • Hepatitis B
  • Poliomyelitis
  • Diphtheria
  • Pertussis
  • Tetanus
  • Haemophilus influenzae type B
  • Pneumococcal disease
  • Rotavirus
  • Measles
  • Human papillomavirus (HPV)
  • Rubella
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2022 ∙ Jaiswal, V. Ang, S. P. Lnu, K. Ishak, A. Pokhrel, N. B. Chia, J. E. Hajra, A. Biswas, M. Matetic, A. Dhatt, R. Mamas, M. A.

Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

  • Adolescents
  • Adults
  • Older adults
  • Pneumococcal disease
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2022 ∙ Lenzing, E. Rezahosseini, O. Burgdorf, S. K. Nielsen, S. D. Harboe, Z. B.

Efficacy, immunogenicity, and evidence for best-timing of pneumococcal vaccination in splenectomized adults: a systematic review

  • Adults
  • Older adults
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
Loading...